SK280537B6 - Použitie derivátov xantínu na výrobu liečiv na oše - Google Patents

Použitie derivátov xantínu na výrobu liečiv na oše Download PDF

Info

Publication number
SK280537B6
SK280537B6 SK2160-92A SK216092A SK280537B6 SK 280537 B6 SK280537 B6 SK 280537B6 SK 216092 A SK216092 A SK 216092A SK 280537 B6 SK280537 B6 SK 280537B6
Authority
SK
Slovakia
Prior art keywords
straight
alkyl
carbon chain
branched
carbon atoms
Prior art date
Application number
SK2160-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK216092A3 (en
Inventor
Hans-Peter Schubert
John J. Grome
Barbara Kittner
Karl Rudolphi
Ulrich Gebert
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of SK216092A3 publication Critical patent/SK216092A3/sk
Publication of SK280537B6 publication Critical patent/SK280537B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK2160-92A 1991-07-11 1992-07-10 Použitie derivátov xantínu na výrobu liečiv na oše SK280537B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4122884 1991-07-11
DE4217639 1992-05-28

Publications (2)

Publication Number Publication Date
SK216092A3 SK216092A3 (en) 1995-09-13
SK280537B6 true SK280537B6 (sk) 2000-03-13

Family

ID=25905369

Family Applications (1)

Application Number Title Priority Date Filing Date
SK2160-92A SK280537B6 (sk) 1991-07-11 1992-07-10 Použitie derivátov xantínu na výrobu liečiv na oše

Country Status (20)

Country Link
US (1) US5409935A (cs)
EP (1) EP0528164B1 (cs)
JP (1) JP3436547B2 (cs)
KR (1) KR100237945B1 (cs)
AT (1) ATE138573T1 (cs)
AU (1) AU649851B2 (cs)
CA (1) CA2073633C (cs)
CZ (2) CZ81696A3 (cs)
DE (1) DE59206403D1 (cs)
DK (1) DK0528164T3 (cs)
ES (1) ES2088519T3 (cs)
GR (1) GR3020233T3 (cs)
HU (1) HU217983B (cs)
IE (1) IE74888B1 (cs)
IL (1) IL102456A (cs)
MX (1) MX9203323A (cs)
PH (1) PH30341A (cs)
RU (1) RU2126407C1 (cs)
SK (1) SK280537B6 (cs)
TW (1) TW210285B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
ES2191013T3 (es) * 1992-03-04 2003-09-01 Cell Therapeutics Inc Compuestos de xantina enantiomeros hidroxilados.
US5567704A (en) * 1992-03-04 1996-10-22 Cell Therapeutics, Inc. R-enatiomerically pure hydroxylated xanthine compounds to treat baldness
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
WO1995013075A1 (en) 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
EP1246808B1 (de) * 2000-01-14 2011-08-17 Bayer Schering Pharma Aktiengesellschaft 1,2-diarylbenzimidazole zur behandlung von erkrankungen die mit einer microglia-aktivierung assoziiert sind
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CH608236A5 (cs) * 1974-01-22 1978-12-29 Wuelfing J A Fa
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
JPS6110715A (ja) * 1984-06-26 1986-01-18 Fanuc Ltd 絶対位置検出方式
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono

Also Published As

Publication number Publication date
EP0528164B1 (de) 1996-05-29
CZ216092A3 (en) 1993-01-13
CZ281480B6 (cs) 1996-10-16
JP3436547B2 (ja) 2003-08-11
HU217983B (hu) 2000-05-28
TW210285B (cs) 1993-08-01
ES2088519T3 (es) 1996-08-16
KR100237945B1 (ko) 2000-02-01
PH30341A (en) 1997-04-02
JPH05186350A (ja) 1993-07-27
IL102456A (en) 1996-10-16
DK0528164T3 (da) 1996-09-30
RU2126407C1 (ru) 1999-02-20
AU649851B2 (en) 1994-06-02
GR3020233T3 (en) 1996-09-30
CA2073633A1 (en) 1993-01-12
CZ282140B6 (cs) 1997-05-14
EP0528164A2 (de) 1993-02-24
ATE138573T1 (de) 1996-06-15
US5409935A (en) 1995-04-25
SK216092A3 (en) 1995-09-13
EP0528164A3 (cs) 1994-03-02
IE74888B1 (en) 1997-08-13
CA2073633C (en) 2003-09-23
HU9202273D0 (en) 1992-10-28
AU1959192A (en) 1993-01-14
IE922259A1 (en) 1993-01-13
CZ81696A3 (en) 1997-05-14
MX9203323A (es) 1994-07-29
DE59206403D1 (de) 1996-07-04
IL102456A0 (en) 1993-01-14
KR930001911A (ko) 1993-02-22
HUT61763A (en) 1993-03-01
RU94027686A (ru) 1996-05-27

Similar Documents

Publication Publication Date Title
RU2159231C2 (ru) 2,4-ДИСУЛЬФОНИЛ-α-ФЕНИЛ-ТРЕТ-БУТИЛНИТРОН, ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ЕГО ФОРМА СВОБОДНОЙ КИСЛОТЫ ИЛИ СОЛЕВАЯ ФОРМА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ
CA2173974C (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
SK280537B6 (sk) Použitie derivátov xantínu na výrobu liečiv na oše
AU764942B2 (en) (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain
JP6860677B2 (ja) グローコカリキシンａ誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用
CS233740B2 (en) Processing of 3-benzazepin compositions
CN100502871C (zh) 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
JPH04264030A (ja) 抗喘息剤
DE69919478T2 (de) 7-Aminopyrido(2,3-d)-pyrimidine Derivate zur Behandlung von Bronchialasthma
EP0865790A2 (en) Use of triazolopyridazine derivatives in the manufacture of a medicament for the treatment of atopic dermatitis
EP0413751A1 (en) Neurologically active compounds
US4188398A (en) Method for treating epilepsy
CN112457291A (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
US3900564A (en) Ocotea alkaloid for relief of anxiety
CN111960978A (zh) 一种具有神经保护活性的s-烯丙基-l-半胱氨酸取代酪醇衍生物合成方法及其应用
DE68912159T2 (de) Dioxoquinazolinderivat enthaltendes Antihypertensivum.
US3629418A (en) Process for producing an anti-depressant effect with piperazine quinolines
DE69630561T2 (de) Verwendung von 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidin zur Herstellung eines blutdrucksenkenden Mittels
DE3884878T2 (de) Uricosuretische Zusammensetzung.
DE3823345A1 (de) 6-merkaptopurin-derivate, ihre herstellung und ihre verwendung zur bekaempfung von retrovirusinfektionen
JPS6117832B2 (cs)
US3711485A (en) Method for extraction of the ocotea alkaloid,glaziovine
JPS6259090B2 (cs)
RU2080862C1 (ru) Ингибитор внутриклеточного образования свободных радикалов
EP0547508A1 (de) Verwendung von Xanthinderivaten zur Stabilisierung der Gehirndurchblutungsautoregulation

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20120710